CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Brentuximab Vedotin|
|Strength||50 mg / vial|
|Indication||Peripheral T-cell Lymphoma (PTCL)|
|Funding Request||For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).|
|Pre Noc Submission||Yes|
|NOC Date||November 22, 2019|
|Manufacturer||Seattle Genetics, Inc.|
|Sponsor||Seattle Genetics, Inc.|
|Submission Date||October 8, 2019|
|Submission Deemed Complete||October 23, 2019|
|Stakeholder Input Deadline ‡||October 23, 2019|
|Check-point meeting||January 7, 2020|
|pERC Meeting||March 19, 2020|
|Initial Recommendation Issued||April 2, 2020|
|Feedback Deadline ‡||April 17, 2020|
|pERC Reconsideration Meeting||May 21, 2020|
|Final Recommendation Issued||June 4, 2020|
|Notification to Implement Issued||June 19, 2020|
|Therapeutic Area||peripheral T-cell lymphoma (PTCL)|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.